Hormonal
Once-weekly semaglutide 2.4 mg delivers significant weight loss (approx. 15-16% in non-diabetics, 9.6% in diabetics) and improves cardiovascular risk factors, and is FDA-approved for chronic weight management in adults with BMI ≥30 kg/m2 or ≥25 kg/m2 with comorbidities.
If you have type 2 diabetes and struggle with weight, once-weekly semaglutide 2.4 mg is a highly effective, FDA-approved option. It can lead to nearly 10% body weight loss when combined with lifestyle changes. While you may experience some gastrointestinal side effects, most people tolerate it well enough to stay on the medication, which is crucial for maintaining the weight loss and improving heart health markers.
Thus, once weekly semaglutide 2.4 mg delivers impressive weight loss and cardiovascular risk factor improvement and is FDA approved for chronic weight management in adults with BMI ≥30 kg/m2 or BMI ≥25 kg/m2 with a comorbid condition (ie, T2D, hypertension, hyperlipidemia).
Why this rating
Based on multiple large randomized controlled trials (STEP 1, 2, 3, 4) with consistent results.
Source
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph et al. · Circulation · 2022
DOI 10.1161/cir.0000000000001040
More from this paper
- Intensive lifestyle intervention in adults with type 2 diabetes and overweight/obesity produces moderate, sustained weight loss and cardiovascular risk factor control, with significant cardiovascular benefits observed specifically in patients achieving >10% weight loss or >2 MET fitness increase in the first year.Good
- Metabolic surgery (bariatric surgery) is recommended for patients with type 2 diabetes and BMI ≥40 kg/m2, or BMI 35.0-39.9 kg/m2 without durable weight loss, and should be considered for BMI 30.0-34.9 kg/m2 without similar improvements, offering superior glycemic control and cardiovascular risk factor reduction compared to lifestyle/medical interventions.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →